Table 2 Clinical and pathological characteristics of the TAm-Seq study cohort
n | 189 |
|---|---|
Age (years) | |
 Median | 63 |
 IQR | 58–67.6 |
PSA ng/ml | |
 Median | 7.5 |
 IQR | 5.3–12.95 |
cT | |
 1 | 105 (55.6%) |
 2 | 63 (33.3%) |
 3 | 21 (11.1%) |
Biopsy ISUP Grade Group | |
 1 | 33 (17.5%) |
 2 | 61 (32.3%) |
 3 | 29 (15.3%) |
 4 | 35 (18.5%) |
 5 | 31 (16.4%) |
pT | |
 2 | 88 (46.6%) |
 3a | 60 (31.7%) |
 3b | 41 (21.7%) |
Prostatectomy ISUP Grade Group | |
 1 | 10 (5.3%) |
 2 | 63 (33.3%) |
 3 | 61 (32.3%) |
 4 | 11 (5.8%) |
 5 | 44 (23.3%) |
Tumour volume (cc) | |
 Median | 3.35 |
 IQR | 1.5–7.37 |
Biochemical recurrence | |
 No | 90 (47.6%) |
 Yes | 99 (52.4%) |
Metastases | |
 No | 117 (61.9%) |
 Yes | 49 (35.9%) |
 Not reported | 23 (12.2%) |